98%
921
2 minutes
20
Chronic limb-threatening ischemia (CLTI), the severest stage of peripheral artery disease, frequently necessitates amputation. In CLTI patients, heart failure with reduced ejection fraction (HFrEF) markedly raises mortality risk, with increased peripheral vascular resistance contributing to this exacerbation. This investigation aimed to assess the impact of major amputation (MA) on the cardiovascular (CV) prognosis in CLTI patients with HFrEF by lowering peripheral vascular resistance. Conducting a retrospective, observational analysis at a single center, a total of 60 patients with CLTI and HFrEF (EF < 50%) who underwent endovascular therapy (EVT) at our institution were assessed. We compared CV outcomes in CLTI patients with HFrEF who received MA (n = 17) to those who did not (n = 43) after undergoing EVT. During the follow-up period, which median 641 (IQR: 245 to 1,734) days post-EVT, a composite primary endpoint of CV death or hospitalization for HF was observed. During the study period, 19 patients (32%) were admitted for HF or died as a consequence of CV events. Kaplan-Meier analysis revealed a significantly reduced incidence of the primary endpoint in the MA cohort (log-rank test: p = 0.035). Adjustments for age and sex showed MA was significantly linked to improved CV prognosis (HR: 0.19; 95% confidence interval: 0.04 to 0.87). A nonsignificant trend toward decreased overall mortality was noted in the MA group, with infections being the predominant cause of death across both groups. In conclusion, in CLTI patients with HFrEF, MA might be linked to reduced CV events, proposing it as a potential definitive strategy for improving CV outcomes in this high-risk population.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.amjcard.2024.12.031 | DOI Listing |
Ann Vasc Surg
September 2025
Department of Cardiovascular Surgery, Hiroshima University Hospital, 1-2-3Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
Background: Polypharmacy or hyperpolypharmacy in elderly patients has been associated with poor prognosis and cardiovascular events due to side effects and drug interactions. Patients with chronic limb-threating ischemia (CLTI) have many comorbidities that may need multiple drugs. The purpose of this study is to evaluate clinical outcomes in these patients with or without hyperpolypharmacy.
View Article and Find Full Text PDFJ Vasc Surg
September 2025
Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, Yale School of Medicine, New Haven, CT.
Introduction: Although smoking cessation has been shown to improve outcomes after lower extremity revascularization (LER), the impact of cessation duration has not been well defined. This study investigates the impact of two cessation durations on LER outcomes in patients with chronic limb-threatening ischemia (CLTI).
Methods: The Peripheral Vascular Intervention, Infrainguinal Bypass, and Suprainguinal Bypass modules of the Vascular Quality Initiative (VQI) were utilized to identify patients whose first recorded LER occurred between 2016-2024 for CLTI.
J Vasc Surg
August 2025
Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, Yale University School of Medicine, New Haven, CT. Electronic address:
Objectives: Diabetes mellitus (DM) is a major risk factor for amputation in patients with chronic limb-threatening ischemia (CLTI) undergoing lower extremity revascularization (LER). Observational studies comparing patients with DM based on insulin therapy have reported inconsistent findings. This study compares the outcomes of patients with insulin-requiring DM (IRDM) and non-insulin requiring DM (NIRDM) based on high quality prospective data.
View Article and Find Full Text PDFPort J Card Thorac Vasc Surg
August 2025
Department of Angiology and Vascular Surgery, Hospital Beatriz Ângelo, Portugal.
Objective: The purpose of this article was to evaluate the clinical impact of diabetic foot ulcer (DFU) severity in patients with chronic limb-threatening ischemia (CLTI) who underwent distal open revascularization.
Methods: This study included a single-center retrospective analysis of diabetic patients with CLTI who underwent distal revascularization between January 2012 and December 2019. The sample was divided into two groups according to DFU severity; group 1 was defined if observed Wound grade ≥ 2 and Infection grade ≥ 1 and group 2 was defined if observed Wound grade < 2 and Infection grade < 1, according to Wound, Ischemia, and foot Infection (WIfI) classification.
Port J Card Thorac Vasc Surg
August 2025
Angiology and Vascular Surgery Department, Vila Nova de Gaia/Espinho Hospital, Portugal.
Introduction: Lower extremity peripheral artery disease (PAD) is associated with a high risk of cardiovascular and limb adverse events. Optimal post intervention antithrombotic strategy may significantly impact medium to long-term outcomes. The VOYAGER PAD trial showed a clinical benefit of combining low dose rivaroxaban plus aspirin by reducing cardiovascular and limb major adverse events.
View Article and Find Full Text PDF